

Programme OIFE Webinar
Update on clinical trials in osteogenesis imperfecta
22 October 2024, 19:30-21:00 CET

19:30	Welcome and introduction <i>Ingunn Westerheim (OIFE)</i>
	<i>Moderators:</i>
19:35 – 19:55 (4 min for Q&A)	Update on Orbit: Clinical Study to assess efficacy and safety of Setrusumab in individuals with Osteogenesis Imperfecta ages 5 – 26 <i>Stan Krolczyk, Vice President, Global Clinical Development</i> Update on Cosmic: Clinical Study to evaluate the effect of Setrusumab versus IV – Bisphosphonate in children with Osteogenesis Imperfecta <i>Stan Krolczyk, Vice President, Global Clinical Development</i> <i>(Questions taken together after both talks)</i>
19:55 – 20:10 (3 min for Q&A)	Update on EVENITY Ph3 study (romosozumab in children with OI) <i>Diala El-Maouche, Clinical Research Medical Director, Bone TA</i>
	<i>Moderators:</i>
20:10 – 20:20 (2 min for Q&A)	TOPaZ, Treatment of Osteogenesis Imperfecta with Teriparatide and Zoledronic Acid Trial <i>Stuart Ralston, Professor of Rheumatology, University of Edinburgh, and Chief Investigator, TOPAZ Trial</i>
20:20 – 20:30 (2 min for Q&A)	The BOOSTB ₄ Clinical Trial <i>BOOST Pharma</i> <i>Cecilia Götherström, Associate Professor, CLINTEC/Karolinska Institutet</i>
20:30 – 20:40 (2 min for Q&A)	The MOI-A trial (Losartan) <i>Professor Nick Bishop, University of Sheffield</i>
20:40 – 20:45 1 min for Q&A	Osteoanabolic treatment in OI caused by WNT mutations (Germany only) <i>Professor Oliver Semler, University of Cologne (Köln)</i>
20:45 – 20:50	Paediatric Cross-Border Clinical Trials (video recorded talk) <i>Begonya Nafria Escalera, Patient Engagement in Research Coordinator at Sant Joan de Déu Children's Hospital (Spain).</i>
20:50 – 21:00	Q&A and closure